Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703192 · ClinicalTrials.gov registry record · Phase 2
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
A Phase 2 study of Adult T-cell Leukemia/Lymphoma and Relapsed/Refractory Peripheral T-cell Lymphoma, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT04703192 is a Phase 2 study of Adult T-cell Leukemia/Lymphoma and Relapsed/Refractory Peripheral T-cell Lymphoma that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 155 participants, above the 29-participant average among 7 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (434% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04703192, a Phase 2 study of Adult T-cell Leukemia/Lymphoma and Relapsed/Refractory Peripheral T-cell Lymphoma, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Conditions Studied
Interventions
- DRUG Valemetostat Tosylate
Study Locations (20)
Other
- Epworth Healthcare - Richmond
- Ottawa Hospital Research Institute - Ottawa
- University Health Network Princess Margaret Hospital - Toronto
- CHU de Dijon - Dijon
- CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang - Lille
California
- City Of Hope National Medical Center - Duarte
- Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY - Palo Alto
- University of California San Francisco - San Francisco
New York
- Memorial Sloan-Kettering Cancer Center at Memorial Hospital - New York
- Weill Cornell Medicine - New York
Colorado
- University Of Colorado Cancer Center - Aurora
Georgia
- Emory University Hospital - Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Feinberg School of Medicine - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2021-06-03 |
| Est. Completion | 2027-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04703192
The ClinicalTrials.gov registry entry for NCT04703192 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 29-participant average among 7 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (434% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adult T-cell Leukemia/Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Valemetostat Tosylate is the first listed.
NCT04703192 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04703192 about?
NCT04703192 is a clinical study titled "Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)". This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
What is the current status of trial NCT04703192?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2021-06-03. Estimated completion is 2027-02-19.
What conditions does trial NCT04703192 study?
This clinical trial studies the following conditions: Adult T-cell Leukemia/Lymphoma, Relapsed/Refractory Peripheral T-cell Lymphoma.
What interventions are being tested in trial NCT04703192?
The interventions under investigation include: Valemetostat Tosylate (DRUG).
Who is sponsoring clinical trial NCT04703192?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04703192 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult T-cell Leukemia/Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
COMPLETED · Phase 2
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Adult T-cell Leukemia/Lymphoma
All registered trials for this condition
Relapsed/Refractory Peripheral T-cell Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.